N/A
N=109
Multifocal High ADD Contact Lens Proof of Concept Trial
Presbyopia
Bottom Line
View on ClinicalTrials.gov: NCT02117544 ↗Enrolled (actual)
109
Serious AEs
0.0%
Results posted
Aug 2015
Primary outcome: Primary: High Contrast Visual Acuity (HCVA) Near Monocular — 0.18; 0.32 logMAR
Study Design & Population
- Study type
- Interventional
- Phase
- N/A
- Interventions
- Lotrafilcon B multifocal contact lenses (new) (Device); Lotrafilcon B multifocal contact lenses (Device)
- Age
- Adult, Older Adult · 50+ yrs
- Sex
- All
- Sponsor
- Alcon Research
- Primary completion
- Jul 2014
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY High Contrast Visual Acuity (HCVA) Near Monocular |
0.18; 0.32 | — |
| SECONDARY HCVA Distance Monocular |
0.11; 0.06 | — |
| SECONDARY HCVA Intermediate Monocular |
0.04; 0.02 | — |
| SECONDARY Low Contrast Visual Acuity (LCVA) Distance Monocular |
0.44; 0.39 | — |
Summary
The purpose of this study is to evaluate the visual performance of a new multifocal High ADD contact lens compared to the currently-marketed AIR OPTIX® AQUA MULTIFOCAL (AOAMF) High ADD Contact Lens.
Eligibility Criteria
Inclusion Criteria
- Must sign an Informed Consent document;
- Presbyopic and require at least 2.25 diopters (D) spectacle ADD power;
- Current or previous soft contact lens wearer;
- Not able to achieve monocular near visual acuity (VA) 0.2 logarithm of the Minimum Angle of Resolution (logMAR) [Early Treatment of Diabetic Retinopathy Study (ETDRS)] or better in each eye with AIR OPTIX® AQUA Multifocal (AOAMF) High ADD Contact Lenses;
- Willing and able to wear multifocal contact lenses in both eyes within the available range of powers for this trial;
- Manifest cylinder less than or equal to 1.00 D;
- Able to achieve best corrected visual acuity (BCVA) of 20/25 or better in each eye at distance (as determined by manifest refraction);
- Other protocol-defined inclusion criteria may apply.
Exclusion Criteria
- Any anterior segment infection, inflammation, disease, or abnormality that contraindicates contact lens wear within 6 months prior to enrollment, as determined by the investigator;
- Any use of systemic or ocular medications for which contact lens wear could be contraindicated, as determined by the investigator; or any use of topical ocular medications that would require instillation during contact lens wear;
- Any history of herpetic keratitis;
- History of corneal or refractive surgery, irregular cornea or unilateral pseudophakia;
- Biomicroscopy findings (except for corneal vascularization) that are moderate (Grade 3) or severe (Grade 4);
- Corneal vascularization that is mild (Grade 2) or higher;
- A pathologically dry eye that precludes contact lens wear;
- Monocular (only 1 eye with functional vision);
- Anisometropia ≥ 1.50 D (contact lens distance prescription);
- Clinically significant (> 1 millimeter) anisocoria;
- History of intolerance or hypersensitivity to any component of the investigational products;
- Concurrent participation in a contact lens or contact lens care product clinical trial within the previous 30 days;
- Eye injury or ocular or intra-ocular surgery within 6 months prior to enrollment;
- Any ocular or systemic medical condition that may, in the opinion of the Investigator, preclude safe administration of the study lenses or affect the results of this study;
- Other protocol-defined exclusion criteria may apply.
Data sourced from ClinicalTrials.gov (NCT02117544). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.